FY2025 EPS Estimates for Legend Biotech Lifted by Analyst

Legend Biotech Co. (NASDAQ:LEGN) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Legend Biotech in a research note issued on Wednesday, October 16th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn $0.12 per share for the year, up from their prior estimate of $0.10. HC Wainwright has a “Buy” rating and a $73.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.51) per share.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.49. The company had revenue of $186.50 million for the quarter, compared to analyst estimates of $125.25 million. Legend Biotech had a negative net margin of 62.50% and a negative return on equity of 23.20%. The company’s revenue was up 154.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.27) earnings per share.

Several other equities analysts have also recently weighed in on the company. TD Cowen dropped their price objective on Legend Biotech from $71.00 to $67.00 and set a “buy” rating for the company in a report on Monday, July 15th. Scotiabank boosted their target price on shares of Legend Biotech from $70.00 to $76.00 and gave the stock a “sector outperform” rating in a research note on Monday, August 12th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Legend Biotech in a research note on Wednesday, July 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 target price on shares of Legend Biotech in a research report on Friday, September 27th. Finally, Redburn Atlantic assumed coverage on shares of Legend Biotech in a report on Tuesday, October 8th. They set a “buy” rating and a $86.00 price target for the company. Fourteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $82.08.

Legend Biotech Price Performance

Legend Biotech stock opened at $42.87 on Friday. Legend Biotech has a 12 month low of $38.60 and a 12 month high of $70.13. The company has a current ratio of 4.84, a quick ratio of 4.78 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $7.81 billion, a price-to-earnings ratio of -32.98 and a beta of 0.10. The stock’s 50 day moving average is $51.44 and its 200-day moving average is $49.31.

Hedge Funds Weigh In On Legend Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Legend Biotech by 1.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,949,120 shares of the company’s stock valued at $614,137,000 after purchasing an additional 140,904 shares in the last quarter. RA Capital Management L.P. grew its holdings in shares of Legend Biotech by 9.5% during the 1st quarter. RA Capital Management L.P. now owns 6,861,097 shares of the company’s stock worth $384,839,000 after acquiring an additional 596,390 shares during the period. Wellington Management Group LLP raised its position in shares of Legend Biotech by 71.6% in the 4th quarter. Wellington Management Group LLP now owns 2,306,391 shares of the company’s stock worth $138,776,000 after acquiring an additional 962,381 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of Legend Biotech by 26.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 2,239,774 shares of the company’s stock valued at $125,629,000 after purchasing an additional 463,527 shares during the period. Finally, Capital International Investors boosted its position in shares of Legend Biotech by 19.5% during the first quarter. Capital International Investors now owns 2,181,074 shares of the company’s stock valued at $122,336,000 after purchasing an additional 356,387 shares in the last quarter. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).